Clinical Trials
408 trialsA Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
LUPARPED
Fundación de investigación HM
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
68Ga-DOTATATE Neuroblastoma Imaging Pilot
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
SABRE
Children's National Research Institute
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Seattle Children's Hospital
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
Universitaire Ziekenhuizen KU Leuven
MRG003
Sun Yat-sen University
BEACON
University of Birmingham
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Stanford University
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Massachusetts General Hospital
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
St. Jude Children's Research Hospital
NEUROBLU 02
Institut Claudius Regaud
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
PEDS-PLAN
Milton S. Hershey Medical Center
MiniVan
University Hospital Southampton NHS Foundation Trust
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
PEACH
University of Florida
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
MAGNETO
University College, London
SJFAMILY
St. Jude Children's Research Hospital
VEGAS
Baylor College of Medicine
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Shaare Zedek Medical Center
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
NYMC195
New York Medical College
ANTARES
Instituto do Cancer do Estado de São Paulo
PEEL-224
Children's Hospital of Philadelphia
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation
New Approaches to Neuroblastoma Therapy Consortium
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
IV Fenretinide
New Approaches to Neuroblastoma Therapy Consortium
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
Sun Yat-sen University
ThINKK-01
St. Justine's Hospital
GRAIN
Baylor College of Medicine
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Mayo Clinic
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
Neuroblastoma Biology Study
New Approaches to Neuroblastoma Therapy Consortium
N2013-02
New Approaches to Neuroblastoma Therapy Consortium